GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » 3-Year RORE %

Trinity Biotech (Trinity Biotech) 3-Year RORE % : 16.38% (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Trinity Biotech's 3-Year RORE % for the quarter that ended in Sep. 2023 was 16.38%.

The industry rank for Trinity Biotech's 3-Year RORE % or its related term are showing as below:

TRIB's 3-Year RORE % is ranked better than
76.67% of 210 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.215 vs TRIB: 16.38

Trinity Biotech 3-Year RORE % Historical Data

The historical data trend for Trinity Biotech's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech 3-Year RORE % Chart

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.53 -12.13 -24.12 -82.22 55.82

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.52 55.82 44.09 36.49 16.38

Competitive Comparison of Trinity Biotech's 3-Year RORE %

For the Diagnostics & Research subindustry, Trinity Biotech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's 3-Year RORE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's 3-Year RORE % falls into.



Trinity Biotech 3-Year RORE % Calculation

Trinity Biotech's 3-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -3.74--1.928 )/( -11.063-0 )
=-1.812/-11.063
=16.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 3-year before.


Trinity Biotech  (NAS:TRIB) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Trinity Biotech 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.